Search

KR-102964080-B1 - Composition for treating atopic dermatitis disease comprising an arylethene derivative as an active ingredient

KR102964080B1KR 102964080 B1KR102964080 B1KR 102964080B1KR-102964080-B1

Abstract

The present invention relates to a pharmaceutical composition for the treatment or prevention of atopic dermatitis comprising, as an active ingredient, a compound selected from arylethene derivative compounds, pharmaceutically acceptable salts thereof, solvates thereof, or stereoisomers thereof. When an animal model of atopic dermatitis was treated with an arylethene derivative compound, a reduction in dorsal thickness was clearly induced, and the statistical significance thereof was confirmed, so it can be usefully utilized as a treatment for atopic dermatitis.

Inventors

  • 전용현
  • 배주현

Assignees

  • 재단법인 대구경북첨단의료산업진흥재단

Dates

Publication Date
20260513
Application Date
20231103

Claims (6)

  1. delete
  2. delete
  3. A pharmaceutical composition for the treatment or prevention of atopic dermatitis comprising, as an active ingredient, a compound selected from an arylethene derivative compound represented by the following chemical formula 2, a pharmaceutically acceptable salt thereof, a solvate thereof, or a stereoisomer thereof: [Chemical Formula 2]
  4. A cosmetic composition for improving or preventing atopic dermatitis comprising, as an active ingredient, a compound selected from an arylethene derivative compound represented by the following chemical formula 2, a pharmaceutically acceptable salt thereof, a solvate thereof, or a stereoisomer thereof: [Chemical Formula 2]
  5. A health functional food composition for improving or preventing atopic dermatitis comprising, as an active ingredient, a compound selected from an arylethene derivative compound represented by the following chemical formula 2, a pharmaceutically acceptable salt thereof, a solvate thereof, or a stereoisomer thereof: [Chemical Formula 2]
  6. A health functional food composition according to claim 5, characterized in that the health functional food composition is an inner beauty food.

Description

Composition for treating atopic dermatitis comprising an arylethene derivative as an active ingredient The present invention provides a composition for treating atopic dermatitis comprising an arylethene derivative as an active ingredient. Atopic dermatitis is a chronic inflammatory disease that occurs prior to the development of asthma and allergic diseases. Its symptoms vary depending on the concentration, quantitative changes, and activity levels of chemokines, and it refers to the phenomenon of Th2-type lymphocytes invading the lesional skin. Atopic dermatitis can be described as a phenomenon in which the proliferation of keratinocytes occurs abnormally due to immunological factors; when keratinocytes are exposed to IFN-γ (interferon-γ) or TNF-α (tumor necrosis factor-α), abnormal expression of chemokines such as TARC, MDC, and CTACK can be observed. This phenomenon occurs because the infiltration of monocytes/T cells into the skin increases as an inflammatory response takes place. Since it is difficult to treat the root cause of atopic dermatitis, the general approach is to manage symptoms through appropriate treatment and avoid triggers, rather than aiming for a complete cure. Prescriptions for atopic dermatitis primarily involve drug therapy using steroids, antihistamines, and antibiotics. While steroids (corticosteroids) are highly effective due to their anti-inflammatory and immunosuppressive effects, long-term use can lead to side effects such as skin weakening, systemic hormonal symptoms, and addiction. Antihistamines alleviate itching by preventing histamine release from mast cells, but they are used as a temporary measure; long-term use can cause side effects such as insomnia, anxiety, and loss of appetite. Therefore, there is a pressing need to develop a new concept of therapeutic composition for atopic dermatitis that is effective without side effects. Figure 1 shows a schematic diagram of an experiment to confirm the induction of atopy and the drug treatment effect. Figure 2 shows data confirming the effect of an arylethene derivative compound on improving atopic dermatitis (intraperitoneal administration). Figure 3 shows data confirming the effect of an arylethene derivative compound on improving atopic dermatitis through histopathological analysis. Figure 4 shows data confirming the inhibitory effect of plasma IgE secretion in an atopic dermatitis mouse animal model. Figure 5 shows data confirming the effect of an arylethene derivative compound on improving atopic dermatitis (oral administration). The present invention will be described in more detail below. The present invention provides a pharmaceutical composition for treating or preventing atopic dermatitis comprising, as an active ingredient, a compound selected from an arylethene derivative compound represented by the following chemical formula 1, a pharmaceutically acceptable salt thereof, a solvate thereof, or a stereoisomer thereof. [Chemical Formula 1] In the above formula 1, n is one of 0 to 5, and R1 to R3 may each be the same or different and may be one of hydrogen, hydroxy, and (C1-C10)alkyl, and preferably in the above formula 1, n is one of 2 to 4, R1 and R2 are hydroxy, and R3 may be (C1-C5)alkyl. The arylethene derivative compound represented by the above chemical formula 1 may be DN200434 of the following chemical formula 2. [Chemical Formula 2] In another embodiment of the present invention, the pharmaceutical composition may further comprise one or more additives selected from the group consisting of suitable carriers, excipients, disintegrants, sweeteners, coating agents, leavening agents, lubricants, lubricants, flavoring agents, antioxidants, buffers, bacteriostatic agents, diluents, dispersants, surfactants, binders, and lubricants commonly used in the manufacture of pharmaceutical compositions. Specifically, the carrier, excipient, and diluent may be lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil. Solid dosage forms for oral administration include tablets, pills, powders, granules, capsules, etc. These solid dosage forms may be prepared by mixing at least one excipient, for example, starch, calcium carbonate, sucrose or lactose, gelatin, etc., with the above composition. In addition, lubricants such as magnesium stearate and talc may also be used in addition to simple excipients. Liquid preparations for oral administration include suspensions, oral liquids, emulsions, and syrups, and may contain various excipients, such as humectants, sweeteners, flavorings, and preservatives, in addition to commonly used simple diluents like water and liquid paraffin. Preparations for parenteral administration include sterile aqueous solutions, non-aque